We routinely test small molecules, biologics, peptides, and natural extracts for anti-fibrotic, anti-inflammatory, senolytic, senomorphic, or nephroprotective activity, as well as early nephrotoxicity safety screening. Our team advises on solubility, vehicle controls, and concentration range based on your compound’s physicochemical profile.

We work mainly with Human primary cells from defined tissue sources: renal, hepatic, pulmonary, cardiac, and dermal fibroblasts, and human whole blood or isolated immune cells (PBMCs, macrophages). All primary cells are sourced from validated commercial suppliers and characterised before use. Immortalised cell lines are available on request.

Yes. We regularly design multi-assay packages combining efficacy (fibrosis), mechanism (inflammation), and safety (nephrotoxicity) assessments in parallel. This maximises data per compound, supports comprehensive Go/No-Go decisions, and reduces overall cost and timeline compared to sequential studies.

NEPHRIX Biosolutions offers both in vitro assays and validated in vivo CKD rodent models (UUO, IRI, STZ, adenine-induced fibrosis, IgA nephropathy, cisplatin AKI) under one roof. Biomarker endpoints such as KIM-1, NGAL, α-SMA or fibronectin are harmonised across both platforms, enabling direct translational comparison and seamless compound progression without switching CRO providers.